European Biotechnology Magazine Autumn 2024

Berlin, 26 September 2024 – The first half of the year has passed, and experts remain divided on whether the funding downturn has bottomed out or even begun to reverse. The numbers for various therapies in development show stark differences: ADCs and radioligands are on the rise, while cell and gene therapies are seeing sharp declines. Are larger funding rounds and a few IPOs a positive sign for everyone? Amid the optimistic news, one major uncertainty lingers: interest rates. This issue’s cover story explores mergers, acquisitions, and IPOs: is recovery on the horizon?

Other topics in this issue:

• Studies: Synbio and AI identified as key technologies across eleven industry sectors
• Market analysis: Investments in alternative proteins
• European Commission: Ursula von der Leyen outlines priorities for the next term
• SLAS Europe: Innovations in lab automation driving transformation in the biopharmaceutical industry
• EMA: PharmaMar vs EMA: Aplidin – a politically driven scandal?
• RNAissance in drug development
• Regional news
• Updates from BIOTECH Austria, the Society for Laboratory Automation and Screening (SLAS), and the Young European Biotech Network (YEBN)
• SPECIAL: CROs & CDMOs

Read the latest issue here.